Sugar test during surgery may unlock secrets of fatty liver disease
NCT ID NCT07326865
First seen Jan 11, 2026 · Last updated Jun 20, 2026 · Updated 26 times
Summary
This study looks at how the liver reacts to a sugar injection during bariatric surgery in people with obesity, comparing those with and without fatty liver disease (MASLD). Forty adults will receive either a sugar solution or salt water during surgery, and small tissue samples will be taken to measure changes in gene activity. The goal is to understand why MASLD develops and how the liver handles sugar, which could lead to better ways to diagnose or treat the condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MASLD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AMC
RECRUITINGAmsterdam, North Holland, 1105AZ, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
labeled glucose (intravenous)
What this could lead to
If successful, this study could reveal how the liver processes sugar differently in people with MASLD, pointing toward new ways to understand or treat the disease.
What could go wrong
This is a small, early-stage observational study (40 participants) that does not test a treatment. Results may not apply to broader populations or lead directly to therapies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.